These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8222793)

  • 41. The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins.
    Wise R; Andrews JM; Ashby JP; Thornber D
    J Antimicrob Chemother; 1990 Apr; 25(4):541-50. PubMed ID: 2351624
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cefetamet pivoxil vs cefaclor in the treatment of acute otitis media in children.
    Furman S; Berkowicz L; Dippenaar J; Hellenberg DA; Montanus MS; Steinberg A; Schall R
    Drugs; 1994; 47 Suppl 3():21-6. PubMed ID: 7518763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cefpodoxime proxetil, its in vitro antibacterial activity, affinity to bacterial penicillin-binding proteins, and synergy of bactericidal activity with serum complement and mouse-cultured macrophages.
    Yokota T; Suzuki E; Arai K
    Drugs Exp Clin Res; 1988; 14(8):495-500. PubMed ID: 3073932
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field].
    Kimura H; Takeuchi H; Ishikawa H; Hayakawa F; Yamamoto N; Nakao Y; Kuno K
    Jpn J Antibiot; 1989 Jul; 42(7):1593-606. PubMed ID: 2562789
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Study of the bactericidal effect of cefpodoxime using an in vitro pharmacokinetic model].
    Caisson A; Chantot JF
    Pathol Biol (Paris); 1991 Oct; 39(8):774-9. PubMed ID: 1762835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cefetamet pivoxil in otitis media.
    Quevedo A; Sossouhounto R; Kissling M
    ORL J Otorhinolaryngol Relat Spec; 1993; 55(2):93-6. PubMed ID: 8446394
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of oral cefpodoxime proxetil and penicillin V potassium in the treatment of group A streptococcal pharyngitis/tonsillitis. The Cefpodoxime Pharyngitis Study Group.
    Brown RJ; Batts DH; Hughes GS; Greenwald CA
    Clin Ther; 1991; 13(5):579-88. PubMed ID: 1799915
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial.
    Hooton TM; Roberts PL; Stapleton AE
    JAMA; 2012 Feb; 307(6):583-9. PubMed ID: 22318279
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro activity of cefpodoxime against bacterial isolates obtained from patients with cancer.
    Rolston KV; Messer M; Nguyen H; Ho D; LeBlanc B; Bodey GP
    Eur J Clin Microbiol Infect Dis; 1991 Jul; 10(7):581-5. PubMed ID: 1915401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cefpodoxime proxetil: a new, broad-spectrum, oral cephalosporin.
    Chocas EC; Paap CM; Godley PJ
    Ann Pharmacother; 1993 Nov; 27(11):1369-77. PubMed ID: 8286813
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of cefpodoxime proxetil dry syrup in pediatric patients with various infections.
    Muranaka H; Yokoyama M
    J Chemother; 1995 Nov; 7 Suppl 4():127-30. PubMed ID: 8904132
    [No Abstract]   [Full Text] [Related]  

  • 52. Bioavailability of cefpodoxime proxetil with co-administered acetylcysteine.
    Kees F; Wellenhofer M; Bröhl K; Grobecker H
    Arzneimittelforschung; 1996 Apr; 46(4):435-8. PubMed ID: 8740095
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Respiratory tract infections in general practice. Cefpodoxime proxetil in patients with risk factors and concomitant illnesses].
    Kardos P; Wiese K
    MMW Fortschr Med; 2000 Feb; 142(5):41. PubMed ID: 10715939
    [No Abstract]   [Full Text] [Related]  

  • 54. Summary of clinical experience with cefpodoxime proxetil in adults in Japan.
    Kumazawa J
    Drugs; 1991; 42 Suppl 3():1-5. PubMed ID: 1726202
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis.
    Johnson CA; Ateshkadi A; Zimmerman SW; Hughes GS; Craig WA; Carey PM; Borin MT
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2650-5. PubMed ID: 8109931
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical evaluation of cefpodoxime proxetil dry syrup in pediatric cutaneous bacterial infection.
    Terui T; Tagami H
    J Chemother; 1995 Nov; 7 Suppl 4():119-21. PubMed ID: 8904129
    [No Abstract]   [Full Text] [Related]  

  • 57. A multi-institutional study on clinical effectiveness of cefpodoxime proxetil dry syrup in childhood infections.
    Imanaka H; Kitahara T; Yoshinaga M; Miyata K
    J Chemother; 1995 Nov; 7 Suppl 4():131-3. PubMed ID: 8904133
    [No Abstract]   [Full Text] [Related]  

  • 58. Cefpodoxime proxetil for infective exacerbations of chronic obstructive airway disease.
    Alderman CP
    Ann Pharmacother; 1996 Feb; 30(2):196. PubMed ID: 8835062
    [No Abstract]   [Full Text] [Related]  

  • 59. [Reevaluation of current antimicrobials. Cefpodoxime proxetil. Discussion].
    Jpn J Antibiot; 1995 Feb; 48(2):183-90. PubMed ID: 7745807
    [No Abstract]   [Full Text] [Related]  

  • 60. Determination of the etiological organism during acute exacerbations of COPD and efficacy of azithromycin, ampicillin-sulbactam, ciprofloxacin and cefaclor. Turkish Thoracic Society COPD Working Group.
    Umut S; Tutluoglu B; Aydin Tosun G; Müsellim B; Erk M; Yildirim N; Vahapoglu H; Yilmaz N; Arseven O; Türker H; Erelel M; Ilvan A; Göylüsün V; Yilmaz Kuyucu T; Koşar F; Soysal F; Gür A; Unutmaz S; Oztürk S; Akman M
    J Chemother; 1999 Jun; 11(3):211-4. PubMed ID: 10435684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.